HIM
SCPH

Hillsdale Investment Management’s scPharmaceuticals SCPH Stock Holding History

Hillsdale Investment Management’s Portfolio SCPH Stock Details SCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-82,300
Closed -$605K – 643
2020
Q2 		$605K Buy
+82,300
New +$723K 0.06% 289

Other funds holding SCPH

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $44.3M AUM 34.55% 1-Year Est. Return

Hillsdale Investment Management's SCPH Position: Q3 2020 in Review

Hillsdale Investment Management sold out of scPharmaceuticals (SCPH) in Q3 2020, closing a stake of 82,300 shares — an estimated $605K sold.

Hillsdale Investment Management first reported a position in SCPH in Q2 2020 and held it in 1 quarter. The position peaked at $605K in Q2 2020. 51 funds tracked by Wall St. Rank hold SCPH as of Q3 2020.

  • Hillsdale Investment Management reported no remaining scPharmaceuticals position as of Q3 2020 after selling out during the quarter.
  • Hillsdale Investment Management sold 82,300 scPharmaceuticals shares in Q3 2020, an estimated $605K.
  • Hillsdale Investment Management first reported a position in scPharmaceuticals in Q2 2020 and held it in 1 quarter.
  • Hillsdale Investment Management's scPharmaceuticals position peaked at $605K in Q2 2020.
  • 51 funds tracked by Wall St. Rank held scPharmaceuticals as of Q3 2020.

Based on Hillsdale Investment Management's 13F filing for Q3 2020, filed 13 Nov 2020.